Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3

View Full Paper
Ask AI
Bookmark
Share

Authors

RNRubén Niesvizky

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds prolonged treatment interruptions feasible in relapsed multiple myeloma, suggesting effective management of adverse events.

Key Points

  • The majority of patients maintained clinical response despite prolonged treatment interruption, demonstrating elranatamab's durability.
  • Among 28 patients, 67.9% achieved complete response after extended elranatamab treatment interruptions.
  • Observational analysis showed safety assessments and treatment interruptions managed adverse events effectively in relapsed multiple myeloma.
  • Findings suggest further studies on restarting elranatamab after disease progression are warranted.

Cite This Study

Rubén Niesvizky (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df3dhttps://doi.org/10.1182/blood-2025-2269
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial2025 · 8 citations
  2. 2Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis2025
  3. 3Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens2025
  4. 4Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study2025
  5. 5Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma2025 · 8 citations